Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Could aminoglutethimide replace adrenalectomy?

A L Harris

    Breast Cancer Research and Treatment
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Aminoglutethimide (AG), a medical adrenalectomy, is increasingly used in the UK. This review compares AG therapy with surgical adrenalectomy, suggesting surgery is no longer indicated for breast cancer management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Give CNAs a career ladder to climb.

    Provider (Washington, D.C.)·2001
    Same author

    Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.

    British journal of cancer·2001
    Same author

    Exploring hemichannel permeability in vitro.

    Methods in molecular biology (Clifton, N.J.)·2001
    Same author

    Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.

    Oncogene·2001
    Same author

    A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2001
    Same author

    Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

    Cancer research·2001
    Same journal

    Comments on: Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

    Breast cancer research and treatment·2026
    Same journal

    Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

    Breast cancer research and treatment·2026
    Same journal

    Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.

    Breast cancer research and treatment·2026
    Same journal

    Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

    Breast cancer research and treatment·2026
    Same journal

    Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

    Breast cancer research and treatment·2026
    Same journal

    Subjective socioeconomic status moderates the relationship between objective neighborhood disadvantage and quality of life in middle- and older-aged women with breast cancer.

    Breast cancer research and treatment·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Oncology
    • Surgical Oncology

    Background:

    • Surgical adrenalectomy for breast cancer has declined in the UK.
    • Hormonal therapies, like aminoglutethimide (AG), have emerged as alternatives.
    • Patient populations are heterogeneous, necessitating evaluation in previously untreated individuals.

    Purpose of the Study:

    • To compare aminoglutethimide (AG) therapy with surgical adrenalectomy.
    • To evaluate the efficacy of AG in both previously treated and untreated breast cancer patients.
    • To determine if surgical adrenalectomy remains indicated for breast cancer management.

    Main Methods:

    • Review of clinical practice in the United Kingdom.
    • Comparison of aminoglutethimide (AG) therapy and surgical adrenalectomy.

    Related Experiment Videos

  • Analysis of patient data from previously untreated and treated populations.

    • Main Results:

    • Aminoglutethimide (AG) therapy has led to a marked decline in surgical adrenalectomy frequency.
    • Optimal assessment requires evaluation in previously untreated patients due to population heterogeneity.
    • Aminoglutethimide has been compared to adrenalectomy in both previously untreated and treated patient groups.

    Conclusions:

    • Aminoglutethimide (AG) therapy is a viable alternative to surgical adrenalectomy.
    • Surgical adrenalectomy is no longer considered indicated in the management of breast cancer.
    • Further research may focus on optimizing AG therapy protocols.